Effect of blocking Rac1 expression in cholangiocarcinoma QBC939 cells

Xudong Liu and Guangyi Wang
Effect of blocking Rac1 expression in cholangiocarcinoma QBC939 cells

Xudong Liu$^{1,2}$ and Guangyi Wang$^{1}$

$^1$Department of General Surgery, First Clinical Hospital, Jilin University, Changchun, Jilin, China
$^2$Department of Emergency, Affiliated Hospital, Inner Mongolia Medical College, Hohhot, Inner Mongolia, China

Abstract

Cholangiocarcinomas (CCs) are malignant tumors that originate from epithelial cells lining the biliary tree and gallbladder. Ras correlative C3 creotxin substrate 1 (Rac1), a small guanosine triphosphatase, is a critical mediator of various aspects of endothelial cell functions. The objective of the present investigation was to study the effect of blocking Rac1 expression in CCs. Seventy-four extrahepatic CC (ECC) specimens and matched adjacent normal mucosa were obtained from the Department of Pathology, Inner Mongolia Medicine Hospital, between 2007 and 2009. Our results showed that the expression of Rac1 was significantly higher (53.12%) in tumor tissues than in normal tissues. Western blotting data indicated a significant reduction in Rac1-miRNA cell protein levels. Rac1-miRNA cell growth rate was significantly different at 24, 48, and 72 h after transfection. Flow cytometry analysis showed that Rac1-miRNA cells undergo apoptosis more effectively than control QBC939 cells. Blocking Rac1 expression by RNAi effectively inhibits the growth of CCs. miRNA silencing of the Rac1 gene suppresses proliferation and induces apoptosis of QBC939 cells. These results suggest that Rac1 may be a new gene therapy target for CC. Blocking Rac1 expression in CC cells induces apoptosis of these tumor cells and may thus represent a new therapeutic approach.

Key words: Cholangiocarcinomas; RNAi; Rac1

Introduction

Cholangiocarcinomas (CCs) are malignant tumors that originate from epithelial cells lining the biliary tree and gallbladder and grow at any location along the biliary epithelium. For practical purposes, CCs have been classified as either intrahepatic or extrahepatic, with extrahepatic sites further classified as proximal, mid, or distal (1). Intrahepatic CCs (ICCs) grow within the liver, while extra-hepatic CCs (ECCs) originate from the bile duct along the hepatoduodenal ligament. ICCs usually present as masses in the liver, while jaundice is the most common presentation of ECCs (2). CCs are relatively rare tumors, although their incidence is rising worldwide. Several advances in the diagnosis, therapy, and palliative treatment of patients affected with CCs have occurred during the last few decades (3).

The Rho family of small guanosine triphosphatases (GTPases) is a subgroup of the Ras superfamily of GTPases. In this family, Rac1, one of the most extensively studied members, was initially discovered as Ras-related C3 botulinum toxin substrate 1 in 1989 (2). The small GTPase Rac1 is a critical mediator of various aspects of endothelial cell functions (4). Rac1 signaling can affect cell growth through a variety of mechanisms. In addition to its effects on gene expression, Rac1 regulates the production of reactive oxygen species, endothelial permeability and cell adhesion, all of which have been implicated in the deterioration of neurovascular integrity in neurological diseases (3). Recent studies have implicated aberrant Rac1 activity not only in tumorigenesis, but also in neurodegenerative disorders, mental retardation syndromes, cirrhosis of the liver, and cardio-remodeling/hypertension. Rac1 expression levels have been found to be higher than normal in CCs as well as in stomach, breast, and lung cancers (3).

The intracellular signaling roles of Rac1 GTPase have been demonstrated in a body of work carried out in the past two decades (4). It is now established that Rac1, together with other Rho proteins, control the organization of actin cytoskeleton and microtubule dynamics by direct interaction with multiple effector proteins (3). It has also been revealed that Rac1 plays critical roles in integrating signals from extracellular stimuli to the cell nucleus, mediating serum response factor-, bcatenin-, and NF-κB-dependent transcription, and is required during G1 and G2/M cell cycle progression (5).
With these critical roles in cell regulation, it is not surprising that malfunction of Rac1 GTPase-controlled signaling pathways has begun to be associated with many aspects of human diseases including cancer (6). Thus, the possible therapeutic role of Rac1 may represent an important aspect of biomedical research.

At present, the main treatment for ECC is excision of the primary tumor, followed by radiotherapy and chemotherapy (6). In many cases, however, problems such as metastatic lesions and subsequent cancer recurrence are still encountered. Recently, following the development of modern molecular biology, in-depth studies have been conducted to develop new strategies of ECC treatment at the genetic level (7). In particular, RNA interference (RNAi) technology has the potential to become an effective treatment for tumors, and has established a new area of clinical therapy for ECC. In the present study, immunohistochemical staining using a streptavidin-peroxidase method for the Rac1 protein was performed on 74 ECC samples and 17 normal samples in an attempt to explore their roles in ECC. Moreover, a Rac1 targeting small interfering RNA (siRNA) was transferred into human ECC QBC939 cells to investigate its effects on cell proliferation.

Material and Methods

Patients and samples

Seventy-four ECC specimens and matched adjacent normal mucosa were obtained from the Department of Pathology, Inner Mongolia Medicine Hospital, between 2007 and 2009. None of the patients had been treated with radiotherapy or chemotherapy before surgery. Samples were taken from areas of the tumor tissue with no evidence of hemorrhage or putrescence. Samples of matching normal mucosa were collected from the surgical cutting edge, which was approximately 3-5 cm away from the cancerous lesion. The clinical diagnosis of all 74 patients was confirmed by histological examination of the resected surgical specimens. The CC cell line QBC939 was obtained from the Chinese Academy of Sciences.

Immunohistochemistry

Immunohistochemistry was performed as follows: tissue sections were deparaffinized and rehydrated three times for 3 min in xylene, three times for 2 min in 100% ethanol, once for 2 min in 95% ethanol, once for 2 min in 75% ethanol and, finally, twice for 1 min in distilled water. Antigens were recovered by heating the sections in a microwave oven for 15 min, after which the sections were washed three times for 5 min with phosphate-buffered saline (PBS). Endogenous peroxidase activity was blocked by soaking the slides in a solution of 3% hydrogen peroxide for 15 min at room temperature, followed by washing three times for 5 min with PBS. Non-immune goat blood serum (50 µL) was added to each section for 15 min at room temperature, followed by the primary antibodies (Millipore, 50 µL). Slides were incubated overnight at 4°C in a humidified chamber and washed three times for 10 min in PBS. Biotin-labeled secondary antibodies (50 µL) were added to each section and kept for 15 min at 37°C, followed by washing three times for 5 min with PBS. Samples were incubated for 15 min at room temperature and washed three times for 5 min in PBS before the addition of 100 L freshly prepared 3,3-diaminobenzidine for approximately 5-20 min. The reaction was stopped by washing in cold water. Slides were counterstained with hematoxylin, followed by a sealing procedure using neutral gum.

miRNA design

The Rac1-targeting miRNA sequence that was designed as gene bank ID NM_018890 by Invitrogen Company was sense-CACCGACTTCATAAGGGCAGATGC, antisense-GCATGCCGTCTTTGAAGCATGCGCCTTATGAAGTC, loop-TTCAAGACG.

Cell culture

The CC cell line QBC939 was grown as a monolayer in RPMI-1640 (Hyclone) containing 10% fetal bovine serum. Cells were maintained at 37°C in a humidified incubator under a 5% CO2 atmosphere.

Transfection of miRNA

miRNA transfection was performed according to the protocol supplied by the Invitrogen Company. Briefly, 1 x 10^5 cells were seeded into six-well plates containing an antibiotic-free medium and incubated overnight. For each well, 5 µL miRNA was mixed with 125 µL OPTI-MEM I. The mixture was then combined with a solution of 5 µL lipofectamine (Invitrogen Company) in 125 µL OPTI-MEM I. After a 20-min incubation period at room temperature, the mixture was applied to the cells in an appropriate volume of OPTI-MEM I so as to achieve a final concentration of 100 nM for each miRNA. After incubation for 6 h at 37°C, RPMI-1640 supplemented with serum was added to the wells and cells were cultured for an additional 24 h at 37°C before analysis.

Western blotting

Cells were harvested 48 h after transfection, washed with cold PBS, and lysed with a phenylmethanesulfonyl fluoride lysis buffer. After centrifugation at 13,200 g for 30 min, the supernatant was analyzed for protein content using the bicinchoninic acid reagent. Total proteins (50 µg) from each sample were electrophoresed on a 10% SDS-PAGE gel and transferred to a polyvinylidene fluoride membrane. The membranes were blocked with PBS containing 5% fat-free milk and 0.1% Tween-20 for 30 min at room temperature, and then incubated with primary anti-Rac1 antibody for at least 1 h at room temperature, or overnight at 4°C. The membranes were washed three times with PBS containing 0.1% Tween 20, incubated with peroxidase-
Rac1 expression in cholangiocarcinomas

conjugated secondary antibodies, and developed using the ECL reagent (Pierce).

3-(4,5-Dimethylidiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay

Cells were grown in 96-well plates (1 x 10^3 cells/well) and transfected with Rac1-targeting miRNA. Control cells were switched from RPMI-1640 to DMEM containing 0.1% dimethyl sulfoxide (DMSO). At 24, 48, and 72 h following miRNA transfection, 20 µL MTT was added to each well to a final concentration of 0.5%. After a 4-h incubation at 37°C in the dark, 150 µL DMSO was added to each well for 10 min to dissolve the formazan crystals. Absorbance at 490 nm was measured using a microplate reader (EXL800, USA). All experiments were repeated three times. The viability of the miRNA-transfected cells is reported as percent population growth plus the standard error of the mean relative to that of untransfected control cells. Cell death caused by miRNA-transfection was calculated as percent inhibition as follows: % inhibition = (1 - mean experimental absorbance / mean control absorbance) x 100.

Flow cytometry analysis

At 48 h after transfection, samples (1 x 10^6 cells) were fixed in 70% (v/v) ethanol and washed, and RNase (0.25 mg/mL) and Tween 20 (0.1% (v/v)) were added for 30 min at room temperature. The cells were stained with propidium iodide and analyzed using a flow cytometer (EPICS XL; Beckman). Several peaks, including sub-G0-G1, S, and G2/M peaks, were detected on the DNA plots using the Cell Quest software. The sub-G0-G1 peak was assumed to indicate the rate of cell apoptosis.

Statistical analysis

The statistical software package SPSS 13.0 was used and data were analyzed by the χ^2 test or the Fisher exact test. Non-parametric Spearman rank correlation analysis was used to analyze ranked data. The rates were compared using Z tests. A P value <0.05 was regarded as significant.

Results

Expression of the Rac1 protein in ECC

Of the 74 ECC cases analyzed, 17 (22.97%) were highly differentiated adenocarcinomas, 29 (39.19%) moderately differentiated adenocarcinomas, and 28 (37.84%) slightly differentiated adenocarcinomas. In all 17 normal cases, expression of Rac1 was relatively low (Figure 1). On the other hand, the expression of Rac1 in extrahepatic cholangiocarcinomas was significantly higher.

Figure 1. Expression of the Rac1 protein (arrows) in extrahepatic cholangiocarcinomas. A, Slightly differentiated adenocarcinomas; B, moderately differentiated adenocarcinomas; C, highly differentiated adenocarcinomas; D, negative control.
hand, in the three types of differentiated adenocarcinomas, Rac1 expression was substantially higher compared to normal cases. These results confirm that the Rac1 protein is present at significantly higher levels in ICC cases than in normal mucosa (P < 0.01).

Expression of the Rac1 protein in QBC939 cells after transfection with miRNA
The cells positively stained by the anti-Rac1 antibody accounted for 95-99% of the total cell population. The control group showed strongly positive cytoplasmic expression of Rac1 (dark brown-yellow), while the Rac1-miRNA group showed weakly positive cytoplasmic expression (light brown-yellow). Western blotting showed that the Rac1 miRNA-transfected cells expressed significantly less Rac1 than the control groups (Figure 2).

Effect of miRNA on cell proliferation
The proliferation rate of the QBC939 cell line 24, 48, and 72 h after transfection with Rac1-miRNA was significantly higher than that of the control group, as assessed by the MTT assay (Figure 3). These effects were time-dependent and clearly showed that cell proliferation was markedly inhibited in the Rac1-miRNA-transfected group.

Cell apoptosis detected by flow cytometry
To test for apoptotic cells, we used flow cytometry (FCM) to locate apoptotic sub-G0-G1 (M1 value), S, and G2/M peaks 48 h after miRNA transfection. The results showed that, compared to the control group (M1 = 0.59) and the mismatched group (M1 = 0.63), the Rac1-miRNA group displayed an apparent aneuploid peak (M1 = 13.88; Figure 4), thus suggesting ongoing apoptosis in the cells transfected with Rac1-miRNA.

Discussion
CC is the second most common type of liver cancer after hepatocellular carcinoma (7). Biliary tract cancers are challenging to diagnose and treat and chronic inflammation and obstruction of bile ducts may play an important role in the progression of this deadly disease (8). Once diagnosed, CC is commonly treated by surgical resection; however, this option is not always viable (9). Although Rho GTPases have been shown to be required for cellular functions associated with tumor progression and invasiveness, the role of Rho proteins in carcinogenesis and tumor progression in actual patients with cancer remains unconfirmed (7,8). Rac GTPases play significant roles in various cellular processes, including migration, cytokinesis, lamellipodia formation, and cell polarity (3). Different studies have indicated contradictory roles for Rho proteins in tumor progression (10,11). For example, although Rac1 down-regulation was shown to result in the inhibition of migration in most human malignancies, migration was shown to be stimulated in aggressive breast cancer cells where Rac1 was knocked down (7). Rac1 positively regulates transcription at NF-κB transcription factor-dependent promoters and facilitates phosphatidylinositol-3 kinase-dependent activation of AKT ser/thr kinase, thereby permitting the survival of transformed cells (2,9). Rac1 can also influence transformation by regulation of cyclin D1, a cell cycle protein that is frequently overexpressed in cancer (12). High RhoA activities were related to the poor prognosis of several cancers (10), such as liver, esophagus, testicular, and upper urinary tract cancers, as well as ovarian carcinoma, whereas high expression of RhoA indicated favorable outcomes in colorectal cancers and PDAC (13). In addition to tumor types, other factors may also influence how Rho proteins affect cell behaviors.
For example, the extracellular matrix can change the effect of Rac1 in promoting cell-cell adhesion (2). Additionally, Rac1 was colocalized with MMP-9 in CCs, and it may influence the DNA damage induced by cholangiocarcinogenesis (11). In the present study, Rac1 was able to inhibit the growth of ECC cells. The ECC was greatly disrupted when high Rac1 levels were expressed. This is consistent with previous studies reporting that Rac1 can inhibit colitis-related CC progression (12).

RNAi is an important technique that specifically down-regulates the expression of cellular genes and has opened the way to the therapeutic use of siRNAs. In our study, we used RNAi technology to transfet an siRNA targeted against Rac1 into QBC939 cells using Lipofectamine 2000. Western blotting showed that the expression of the Rac1 protein was significantly reduced. Our results indicate that Rac1-siRNA can actively suppress Rac1 protein expression and inhibit cell proliferation, in agreement with current literature (14,15). Blocking Rac1 expression using RNAi resulted in significant inhibition of cell growth in a time-dependent manner. A recent study (14) showed that Rac1 is closely associated with apoptosis. Lin and van Gol (16) found that Rac1 could suppress apoptosis in breast cancer cells. Aznar and Lacal (17) found that Rac1 could up-regulate bcl-2 levels in breast cancer cells, thus inhibiting apoptosis in both tumor cells and vascular endothelial cells. Our results show that the rate of apoptosis was significantly higher in the Rac1-siRNA group than that in the control group. This suggests that siRNA can effectively silence the Rac1 gene and promote apoptosis in QBC939 cells.

Rac1 can promote cytoskeleton construction, intercellular sticking, and intercellular signal transmission, as well as cell proliferation. Rac1 can also increase NAPDH levels and protect cells from apoptosis (13). In the present study, the slightly differentiated adenocarcinoma group had the highest Rac1 expression level and in QBC939 cells, the RNAi group showed more apoptosis than the control group.

Taken together, the present results suggest that Rac1 is associated with CC carcinogenesis. Blocking Rac1 expression using RNAi technology significantly reduced Rac1 protein levels, suppressed the proliferation of QBC939 cells, and induced apoptosis. Our data thus indicate that the use of miRNA targeting Rac1 may have a therapeutic potential for the treatment of ECCs.

Acknowledgments

Research supported by the Inner Mongolia Natural Science Foundation (#NM 006908), The People’s Republic of China.
References


